HISTONE DEACETYLASE 10-INHIBITOR CO-TREATMENT IN CANCER
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Nov 6, 2014
app pub date -
Dec 21, 2012
filing date -
Dec 30, 2011
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present invention relates to a method of identifying a subject being susceptible to a co-treatment with an histone deacetylase 10 (HDAC10)-inhibitor, said subject being in need of and/or being treated with cancer therapy against a cancer, comprising the steps of a) determining the amount of an HDAC10 gene product and/or an autophagy-related gene 4D (ATG4D) product in a cancer sample from said subject, b) comparing the amount of said HDAC10 gene product as determined in step a) with a reference amount for said HDAC10 gene product and/or the amount of ATG4D product as determined in step a) with a reference amount for said ATG4D product, and c) identifying a subject being susceptible to co-treatment with an HDAC10-inhibitor. Moreover, The present invention relates to a method of predicting the risk of recurrence and/or progression of a cancer in an subject treated by cancer therapy, comprising the steps of a) determining the amount of an HDAC10 gene product and/or an ATG4D product in a cancer sample from said subject, b) comparing the amount of said HDAC10 gene product as determined in step a) with a reference amount for said HDAC10 gene product and/or the amount of ATG4D product as determined in step a) with a reference amount for said ATG4D product, and c) predicting the risk of recurrence and/or progression of a cancer treated by cancer therapy. The present invention also relates to a device for identifying a subject being susceptible to co-treatment with an HDAC10-inhibitor, a kit adapted to carry out the method of the present invention. Finally, the invention relates to 2-(4-butoxyphenyl)-N-hydroxyacetamide (bufexamac) for use in treating cancer in a subject, wherein said bufexamac is to be applied in a co-treatment with cancer therapy.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully